Multiple strategies using either T cell-stimulating agents (tumor necrosis factor receptor (TNFR) superfamily antibodies and peptides, e.g., OX-40), genetically modified T cells (Chimeric Antigen Receptor (CAR)-T cells), bi-specific antibodies, and tumor vaccination or agents that counteract the immunosuppressive tumor microenvironment (e.g., inhibitors of TGF-β, as well as Toll-like receptor (TLR) agonists) are currently being tested in preclinical and clinical trials [141,142,143,144,145,146,147,148,149,150]. The gene discussed is TNFRSF1A; the disease is neoplasm.